

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.

DRUG REQUESTED (select one from below):

<input type="checkbox"/> Amturnide® (amlodipine, aliskiren, and HCTZ)	<input type="checkbox"/> Tekamlo® (aliskiren and amlodipine)
<input type="checkbox"/> Azor® (amlodipine and olmesartan)	<input type="checkbox"/> Tekturna® (aliskiren)
<input type="checkbox"/> Benicar® (olmesartan)	<input type="checkbox"/> Tekturna® HCT (aliskiren)
<input type="checkbox"/> Benicar® HCT (olmesartan)	<input type="checkbox"/> Teveten® HCT (eprosartan mesylate);
<input type="checkbox"/> Tribenzor® (olmesartan medoxomil, amlodipine and HCTZ)	

DRUG INFORMATION: Complete information below. If incomplete, authorization process will be delayed.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

CLINICAL CRITERIA: The following criteria **MUST** be met. Check **ALL** boxes that apply. If not checked, authorization process will be delayed.

Patient has tried and failed therapy with **at least one** of the following (*select one*):

<input type="checkbox"/> amlodipine and valsartan	<input type="checkbox"/> eprosartan	<input type="checkbox"/> amlodipine, valsartan, and HCTZ
<input type="checkbox"/> losartan	<input type="checkbox"/> losartan HCTZ	<input type="checkbox"/> candesartan
<input type="checkbox"/> candesartan HCTZ	<input type="checkbox"/> irbesartan	<input type="checkbox"/> irbesartan HCTZ
<input type="checkbox"/> valsartan	<input type="checkbox"/> valsartan HCTZ	<input type="checkbox"/> telmisartan
<input type="checkbox"/> telmisartan HCTZ	<input type="checkbox"/> telmisartan amlodipine	

AND

Patient has tried and failed therapy with Edarbi® or Edarbyclor®

Member will be required to try the prior-therapy drug for a time period of 30 days before moving to the requested step-edit drug.

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Member Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Phone Number: _____ Fax Number: _____

DEA/NPI #: _____

*Approved by Pharmacy and Therapeutics Committee: 1/21/2010

REVISED/UPDATED: 1/20/2011; 9/06/20011; 10/25/2011; 7/1/2012; 1/10/2013; 5/21/2013; 3/20/2014; 8/6/2014; 10/30/2014; 2/9/2015; 5/21/2015; 12/27/2015; 12/4/2016; 9/19/2017.